Reports
Global Rare Haematology Disorders Market Share, Size, Analysis, Research, Report: By Treatment Type: Plasma Derived, Recombinant; By Disease Indication: Haemoglobin Disorders, Rare Blood Cancers, Platelet Based Disorders, Plasma Disorders, Others; By Dosage Form; By Age Group; Regional Analysis; Competitive Landscape; 2024-2032
Global Rare Haematology Disorders Market Outlook
The global rare haematology disorders market is expected to grow at a CAGR of 5.6% in the forecast period of 2024-2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
High Patient Volume in North America to Aid the Market Growth of Rare Haematology Disorders
The market growth for rare haematology disorders is majorly being supported by the North America market. The region is contributing to the growth of the market as it contains a high patient volume, along with offering an option to get reimbursement for rare haematology disorder treatment products. Further, the treatment of this disorder offers a rich pipeline, and the bulk of these clinical trials are processed in the United States. The region is followed by Europe, which is expected to account for the second-largest market for rare haematology disorders across the globe. This position of Europe is owing to the rising presence of key players. Moreover, Europe offers faster approvals of orphan drugs, which decreases the time-to-market, as a result aiding the market growth.
Rare Haematology Disorders: Market Segmentation
The rare haematology disorder is a set of diseases, which include anaemia-type red blood cell conditions, immuno-disorders, white blood cell dysfunctions, and other platelet-based abnormalities. These are caused when the normal process of blood formation fails, and, instead, abnormal blood cell type is produced, which results in blood cancer and other blood disorders.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of treatment type, the market is divided into:
- Plasma Derived
- Recombinant
Based on disease indication, the industry can be segmented into:
- Haemoglobin Disorders
- Rare Blood Cancers
- Platelet Based Disorders
- Plasma Disorders
- Myeloproliferative Disorders
- Genetic Haematology Disorders
- Others
By dosage form, the industry is classified into:
- Oral
- Injectable
- Others
The industry is divided on the basis of age group into:
- Adult (18+)
- Paediatric (0-17)
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Growing Rare Haemoglobin Disorders and Rare Blood Cancers to Aid the Market Growth of Rare Haematology Disorders
The market growth of rare haematology disorders is driven by the growing occurrence of rare haemoglobin disorders and rare blood cancers, which are predicted to contribute to the highest market share owing to the growing number of authorised products for these indications. Further, the rising demand for injectable dosage in the form segment is expected to propel the market growth as many of the new approvals are in injectable dosage forms.
Key Industry Players in the Global Rare Haematology Disorders Market
The report gives a detailed analysis of the following key players in the global rare haematology disorders market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Bristol-Myers Squibb Company
- Novo Nordisk A/S
- F. Hoffmann-La Roche Ltd
- Emmaus Medical, Inc.
- Pfizer Inc.
- Bayer AG
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Treatment Type, Disease Indication, Dosage Form, Age Group, Region |
| Breakup by Treatment Type | Plasma Derived, Recombinant |
| Breakup by Disease Indication | Haemoglobin Disorders, Rare Blood Cancers, Platelet Based Disorders, Plasma Disorders, Myeloproliferative Disorders, Genetic Haematology Disorders, Others |
| Breakup by Dosage Form | Oral, Injectable, Others |
| Breakup by Age Group | Adult (18+), Pediatric (0-17) |
| Breakup by Region | North America, Latin America, Europe, Middle East and Africa, Asia Pacific |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Bristol-Myers Squibb Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emmaus Medical, Inc., Pfizer Inc., Bayer AG, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Rare Haematology Disorders Market Analysis
8.1 Key Industry Highlights
8.2 Global Rare Haematology Disorders Historical Market (2018-2023)
8.3 Global Rare Haematology Disorders Market Forecast (2024-2032)
8.4 Global Rare Haematology Disorders Market by Treatment Type
8.4.1 Plasma Derived
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2023)
8.4.1.3 Forecast Trend (2024-2032)
8.4.2 Recombinant
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2023)
8.4.2.3 Forecast Trend (2024-2032)
8.5 Global Rare Haematology Disorders Market by Disease Indication
8.5.1 Haemoglobin Disorders
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2023)
8.5.1.3 Forecast Trend (2024-2032)
8.5.2 Rare Blood Cancers
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2023)
8.5.2.3 Forecast Trend (2024-2032)
8.5.3 Platelet Based Disorders
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2023)
8.5.3.3 Forecast Trend (2024-2032)
8.5.4 Plasma Disorders
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2023)
8.5.4.3 Forecast Trend (2024-2032)
8.5.5 Myeloproliferative Disorders
8.5.5.1 Market Share
8.5.5.2 Historical Trend (2018-2023)
8.5.5.3 Forecast Trend (2024-2032)
8.5.6 Genetic Haematology Disorders
8.5.6.1 Market Share
8.5.6.2 Historical Trend (2018-2023)
8.5.6.3 Forecast Trend (2024-2032)
8.5.7 Others
8.6 Global Rare Haematology Disorders Market by Dosage Form
8.6.1 Oral
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2023)
8.6.1.3 Forecast Trend (2024-2032)
8.6.2 Injectable
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2023)
8.6.2.3 Forecast Trend (2024-2032)
8.6.3 Others
8.7 Global Rare Haematology Disorders Market by Age Group
8.7.1 Adult (18+)
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2023)
8.7.1.3 Forecast Trend (2024-2032)
8.7.2 Pediatric (0-17)
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2023)
8.7.2.3 Forecast Trend (2024-2032)
8.8 Global Rare Haematology Disorders Market by Region
8.8.1 Market Share
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2023)
9.3.2 Forecast Trend (2024-2032)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2023)
9.4.2 Forecast Trend (2024-2032)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2023)
9.5.2 Forecast Trend (2024-2032)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Bristol-Myers Squibb Company
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Novo Nordisk A/S
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 F. Hoffmann-La Roche Ltd
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Emmaus Medical, Inc.
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Pfizer Inc.
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Bayer AG
11.2.6.1 Company Overview
11.2.6.2 Product Portfolio
11.2.6.3 Demographic Reach and Achievements
11.2.6.4 Certifications
11.2.7 Others
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Rare Haematology Disorders Market: Key Industry Highlights, 2018 and 2032
2. Global Rare Haematology Disorders Historical Market: Breakup by Treatment Type (USD Billion), 2018-2023
3. Global Rare Haematology Disorders Market Forecast: Breakup by Treatment Type (USD Billion), 2024-2032
4. Global Rare Haematology Disorders Historical Market: Breakup by Disease Indication (USD Billion), 2018-2023
5. Global Rare Haematology Disorders Market Forecast: Breakup by Disease Indication (USD Billion), 2024-2032
6. Global Rare Haematology Disorders Historical Market: Breakup by Dosage Form (USD Billion), 2018-2023
7. Global Rare Haematology Disorders Market Forecast: Breakup by Dosage Form (USD Billion), 2024-2032
8. Global Rare Haematology Disorders Historical Market: Breakup by Age Group (USD Billion), 2018-2023
9. Global Rare Haematology Disorders Market Forecast: Breakup by Age Group (USD Billion), 2024-2032
10. Global Rare Haematology Disorders Historical Market: Breakup by Region (USD Billion), 2018-2023
11. Global Rare Haematology Disorders Market Forecast: Breakup by Region (USD Billion), 2024-2032
12. North America Rare Haematology Disorders Historical Market: Breakup by Country (USD Billion), 2018-2023
13. North America Rare Haematology Disorders Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Europe Rare Haematology Disorders Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Europe Rare Haematology Disorders Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Asia Pacific Rare Haematology Disorders Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Asia Pacific Rare Haematology Disorders Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Latin America Rare Haematology Disorders Historical Market: Breakup by Country (USD Billion), 2018-2023.
19. Latin America Rare Haematology Disorders Market Forecast: Breakup by Country (USD Billion), 2024-2032
20. Middle East and Africa Rare Haematology Disorders Historical Market: Breakup by Country (USD Billion), 2018-2023
21. Middle East and Africa Rare Haematology Disorders Market Forecast: Breakup by Country (USD Billion), 2024-2032
22. Global Rare Haematology Disorders Market Structure
Key Questions Answered in the Report
The global rare haematology disorders market is projected to grow at a CAGR of 5.6% between 2024 and 2032.
The market is being driven by rising disposable incomes, growing incidences of rare haemoglobin disorders and rare blood cancers, and the increasing demand for injectable dosages.
The key trends guiding the market include the increasing R&D activities by key players, the surging approvals of injectable dosages, and the introduction of favourable government initiatives aimed at providing reimbursement for rare haematology disorder treatment products.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading treatment types in the market are plasma derived and recombinant.
The major disease indications in the industry are haemoglobin disorders, rare blood cancers, platelet based disorders, plasma disorders, myeloproliferative disorders, and genetic haematology disorders, among others.
The major disease indications considered in the market report include haemoglobin disorders, rare blood cancers, platelet based disorders, plasma disorders, myeloproliferative disorders, and genetic haematology disorders, among others.
The major age group segments in the market are adult (18+) and paediatric (0-17).
The major players in the market are Bristol-Myers Squibb Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emmaus Medical, Inc., Pfizer Inc., and Bayer AG, among others.
Analyst Review
The global rare haematology disorders market is being driven by the rising incidences of rare haemoglobin disorders. Aided by the growing R&D activities, the market is expected to witness a healthy growth in the forecast period of 2024-2032, growing at a CAGR of 5.6%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on treatment type, the market is bifurcated into plasma derived and recombinant. On the basis of disease indication, the industry is divided into haemoglobin disorders, rare blood cancers, platelet based disorders, plasma disorders, myeloproliferative disorders, and genetic haematology disorders, among others. By dosage form, the market is segmented into oral and injectable, among others. Based on age group, the market is bifurcated into adult (18+) and paediatric (0-17). The major regional markets for rare haematology disorders are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Bristol-Myers Squibb Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emmaus Medical, Inc., Pfizer Inc., and Bayer AG, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER